---
document_datetime: 2023-09-21 17:10:11
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/scientific-discussion/adrovance-epar-scientific-discussion_en.pdf
document_name: adrovance-epar-scientific-discussion_en.pdf
version: success
processing_time: 0.5160841
conversion_datetime: 2025-12-28 09:42:02.249004
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## 1. Introduction

This application has been submitted as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended.

Therefore, consent from the MAH of the FOSAVANCE application, which had been submitted as a full application under Art 8(3) of Directive 2001/83/EC as amended, has been given allowing access to Module  2  to  Module  5  of  the  initial  dossier  of  this  authorised  product  and  any  subsequent  postmarketing procedures submitted, assessed and approved.

As a consequence, quality, safety and efficacy of the ADROVANCE medicinal product is identical to the  up-to-date  quality,  safety  and  efficacy  profile  of  FOSAVANCE.  Information  on  the  scientific discussions can be found in the FOSAVANCE CHMP assessment report and in the European Public Assessment Report (EPAR).

The approved indication is: 'Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency. ADROVANCE reduces the risk of vertebral and hip fractures'.

## 2. Quality aspects

Since  this  application  is  an  informed  consent  of  the  FOSAVANCE  application,  the  quality  data  in support  of  the  ADROVANCE  application  are  identical  to  the  up-to-date  quality  data  of  the FOSAVANCE  dossier  which  have  been  assessed  and  approved  (including  all  post-marketing procedures).

## 3. Non-clinical aspects

Since this application is an informed consent of the FOSAVANCE application, the non-clinical data in support  of  the  ADROVANCE  application  are  identical  to  the  up-to-date  non-clinical  data  of  the FOSAVANCE  dossier,  which  have  been  assessed  and  approved  (including  all  post-marketing procedures).

## 4. Clinical aspects

Since  this  application  is  an  informed  consent  of  the  FOSAVANCE  application,  the  clinical  data  in support  of  the  ADROVANCE  application  are  identical  to  the  up-to-date  clinical  data  of  the FOSAVANCE  dossier,  which  have  been  assessed  and  approved  (including  all  post-marketing procedures).

## Â· User consultation

Since this application is an informed consent of the FOSAVANCE application, the user consultation submitted for the ADROVANCE application is identical to the one submitted for the FOSAVANCE dossier, which was considered acceptable by the CHMP.

## 5. Pharmacovigilance

## PSUR

As  requested  by  the  MAH  and  agreed  by  the  CHMP,  the  PSUR  cycle  of  ADROVANCE  will correspond  to  the  one  attributed  to  the  cross-referred  product,  FOSAVANCE,  until  otherwise specified.

## SCIENTIFIC DISCUSSION

<div style=\"page-break-after: always\"></div>

## Detailed description of the Pharmacovigilance system

The  CHMP considered  that  the  Pharmacovigilance  system  as  described  by  the  applicant  fulfils  the legislative requirements.

## Risk Management Plan

The applicant submitted a risk management plan. The CHMP considered that routine pharmacovigilance was adequate to monitor the safety of the product.

The  CHMP,  having  considered  the  data  submitted  in  the  application,  is  of  the  opinion  that  no additional risk minimisation activities are required beyond those included in the product information. However, the applicant is asked to provide an updated Risk Management Plan taken into account the comments raised during the assessment, at the time of the first PSUR.

## 6. Overall conclusions, risk/benefit assessment and recommendation

Since this application is an informed consent of the FOSAVANCE application, the CHMP considered that  the  risk-benefit  balance  of  ADROVANCE  (70  mg  alendronic  acid  as  alendronate  sodium trihydrate and  /70 micrograms colecalciferol) tablet given once weekly was favourable and therefore recommended the granting of the marketing authorisation for the following indication:

'Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency. ADROVANCE reduces the risk of vertebral and hip fractures.'